ArticleEuropean urology open science2026
Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Everolimus has been proved effective in treating renal angiomyolipoma (RAML) associated with tuberous sclerosis complex (TSC). However, its impact on renal function remains uncertain. Methods: We analyzed changes in the estimated glomerular filtration rate (eGFR) in 54 TSC-RAML patients undergoing 1-yr everolimus treatment, based on the data from two previously registered clinical trials. Key findings and limitations: After 1 yr of everolimus treatment, no significant change in eGFR was observed in the overall cohort of 54 patients (102 [81-121] vs 103 [79-122] ml/min/1.73 m Conclusions and clinical implications: Everolimus demonstrates a favorable renal safety profile in TSC-RAML patients and improves renal function in patients with substantial tumor reduction, supporting its use as a therapeutic option for renal function preservation. Patient summary: In this study, we evaluated kidney function in patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC-RAML), who received everolimus treatment. We found that kidney function was generally stable and even improved in patients with marked tumor reduction. These results suggest that everolimus may help preserve or enhance kidney health in selected patients with TSC-RAML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.